Elite Journal of Medical Sciences. Volume 2 issue 5(2024), Pp. 31-39
https://epjournals.com/journals/EJMS

Obesity and Treatment-Related Neurotoxicity in Leukemia Patients with Advanced HIV/AIDS: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Obesity and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) independently pose significant health challenges, and their coexistence complicates the management of comorbid conditions such as leukemia. Leukemia patients with advanced HIV/AIDS are particularly vulnerable to treatment-related neurotoxicity, which can impact cognitive function, quality of life, and treatment outcomes. This review explores the interplay between obesity and treatment-related neurotoxicity in leukemia patients with advanced HIV/AIDS, examining underlying mechanisms, clinical implications, and potential interventions. Chemotherapy-induced neurotoxicity is a common complication in leukemia treatment, with obesity exacerbating its severity through alterations in systemic metabolism, inflammation, and oxidative stress. Obesity-related metabolic disturbances, such as insulin resistance and dyslipidemia, may further impair neuronal function and increase susceptibility to chemotherapy-induced neurotoxicity. Moreover, obesity-related neuroinflammation and adipose tissue-derived cytokines can modulate chemotherapy-induced neurotoxicity, contributing to neuronal damage and cognitive dysfunction. Comprehensive assessment of obesity-related risk factors, such as Body Mass Index (BMI), metabolic parameters, and adipokine levels, is crucial for identifying leukemia patients with advanced HIV/AIDS who are at higher risk of treatment-related neurotoxicity. Targeted interventions aimed at mitigating obesity-related inflammation and oxidative stress, such as dietary modification, physical activity, and pharmacological interventions, may help reduce the incidence and severity of treatment-related neurotoxicity in this vulnerable patient population.

Keywords: *Obesity, treatment-related neurotoxicity, leukemia, HIV/AIDS, comorbidity, chemotherapy, central nervous system, cognitive impairment, neuroinflammation, oxidative stress*

Introduction

Citation: Obeagu EI. Obesity and Treatment-Related Neurotoxicity in Leukemia Patients with Advanced HIV/AIDS: A Review. Elite Journal of Medical Sciences, 2024; 2(5):31-39

Obesity and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) represent two major public health challenges globally, each with significant implications for morbidity and mortality. Obesity, characterized by excess adiposity and associated metabolic dysregulation, is a well-established risk factor for various chronic diseases, including cardiovascular disease, type 2 diabetes, and certain cancers. HIV/AIDS, on the other hand, is a viral infection that progressively compromises the immune system, leading to increased susceptibility to opportunistic infections and malignancies. The coexistence of obesity and advanced HIV/AIDS presents unique clinical complexities, particularly in the management of comorbid conditions such as leukemia.[1-5] Leukemia, a group of hematologic malignancies characterized by the uncontrolled proliferation of abnormal blood cells, poses significant challenges in patients with advanced HIV/AIDS. Treatment-related neurotoxicity, a common complication of leukemia therapy, can manifest as cognitive impairment, peripheral neuropathy, and other neurological symptoms, impacting patient quality of life and treatment outcomes. While the underlying mechanisms of treatment-related neurotoxicity are multifactorial, the presence of obesity and advanced HIV/AIDS may exacerbate its severity through various pathways, including metabolic dysregulation, inflammation, and immune dysfunction.[6-10]

Obesity-related metabolic disturbances, such as insulin resistance and dyslipidemia, may increase susceptibility to chemotherapy-induced neurotoxicity, while HIV/AIDS-associated immune dysfunction and neuroinflammation may further potentiate neurotoxic effects. Therefore, elucidating the specific mechanisms linking obesity, HIV/AIDS, and treatment-related neurotoxicity is crucial for developing targeted interventions aimed at mitigating these risks and improving outcomes in this vulnerable patient population.[11-15] Moreover, the prevalence of obesity and HIV/AIDS continues to rise globally, highlighting the growing importance of addressing the intersection of these conditions in the context of leukemia treatment. As advancements in leukemia therapy continue to improve survival rates, the management of treatment-related complications, such as neurotoxicity, becomes increasingly critical for optimizing long-term outcomes. Therefore, this review aims to provide a comprehensive overview of the current literature on the interplay between obesity and treatment-related neurotoxicity in leukemia patients with advanced HIV/AIDS, examining underlying mechanisms, clinical implications, and potential interventions.[16-20]

Mechanisms of Treatment-Related Neurotoxicity

Treatment-related neurotoxicity is a common and often debilitating complication in leukemia patients undergoing chemotherapy, particularly in those with advanced HIV/AIDS. The mechanisms underlying treatment-related neurotoxicity are complex and multifactorial, involving both direct neurotoxic effects of chemotherapy agents and indirect effects mediated through systemic metabolic disturbances, inflammation, and immune dysregulation.[21-22] Chemotherapy agents used in leukemia treatment can induce neurotoxicity through various mechanisms. Some chemotherapeutic agents, such as platinum-based compounds and vinca alkaloids, exert direct neurotoxic effects by disrupting microtubule function, impairing axonal transport, and inducing neuronal apoptosis. Other agents, such as methotrexate and cytarabine, can cause neurotoxicity through mechanisms involving DNA damage, oxidative stress, and mitochondrial dysfunction in

neuronal cells. Additionally, chemotherapy-induced disruption of the blood-brain barrier may allow for the penetration of neurotoxic agents into the central nervous system, further exacerbating neuronal damage and dysfunction.[23-25] Systemic metabolic disturbances associated with obesity, such as insulin resistance, dyslipidemia, and hyperglycemia, may contribute to chemotherapy-induced neurotoxicity. Insulin resistance, characterized by impaired insulin signaling and glucose metabolism, can lead to neuronal dysfunction and apoptosis, exacerbating chemotherapy-induced neurotoxicity. Dyslipidemia, characterized by alterations in lipid metabolism and increased circulating levels of pro-inflammatory lipids, may promote neuroinflammation and oxidative stress, further exacerbating neuronal damage. Moreover, hyperglycemia, commonly observed in obese individuals, can potentiate chemotherapy-induced neurotoxicity through mechanisms involving oxidative stress, inflammation, and impaired neuronal repair mechanisms.[26-30] In addition to metabolic disturbances, obesity-related inflammation and immune dysregulation may contribute to chemotherapy-induced neurotoxicity. Adipose tissue-derived cytokines, such as leptin and adiponectin, can modulate neuroinflammation and oxidative stress, contributing to neuronal damage and cognitive dysfunction. Moreover, obesity-related immune dysregulation, characterized by chronic low-grade inflammation and alterations in immune cell function, may impair neuronal repair mechanisms and exacerbate chemotherapy-induced neurotoxicity. In the context of HIV/AIDS, immune dysfunction and neuroinflammation associated with advanced disease may further potentiate chemotherapy-induced neurotoxicity, leading to increased susceptibility to cognitive impairment and other neurological complications.[31-33]

Impact of Obesity on Treatment-Related Neurotoxicity

Obesity, characterized by excess adiposity and associated metabolic dysregulation, has a significant impact on treatment-related neurotoxicity in leukemia patients, particularly those with advanced HIV/AIDS. Several mechanisms contribute to the exacerbation of neurotoxicity in obese individuals undergoing chemotherapy, including alterations in systemic metabolism, inflammation, oxidative stress, and blood-brain barrier integrity.[34-36] Firstly, obesity-related metabolic disturbances, such as insulin resistance and dyslipidemia, can increase susceptibility to chemotherapy-induced neurotoxicity. Insulin resistance, a hallmark of obesity, leads to impaired glucose metabolism and neuronal dysfunction, exacerbating chemotherapy-induced neurotoxic effects. Dyslipidemia, characterized by elevated circulating levels of pro-inflammatory lipids, may promote neuroinflammation and oxidative stress, further amplifying neuronal damage and cognitive impairment.[37-39] Moreover, obesity-related chronic inflammation contributes to neurotoxicity by exacerbating chemotherapy-induced neuroinflammation and oxidative stress. Adipose tissue-derived cytokines, such as leptin and adiponectin, modulate neuroinflammatory responses and oxidative stress pathways, potentially enhancing the neurotoxic effects of chemotherapy agents. Additionally, obesity-related immune dysregulation, characterized by alterations in immune cell function and chronic low-grade inflammation, may impair neuronal repair mechanisms and exacerbate chemotherapy-induced neurotoxicity.[40-45]

The impact of obesity on blood-brain barrier integrity further exacerbates treatment-related neurotoxicity in leukemia patients. Obesity is associated with alterations in blood-brain barrier structure and function, leading to increased permeability and enhanced penetration of neurotoxic

chemotherapy agents into the central nervous system. This heightened exposure to chemotherapy agents may result in more severe neurotoxic effects, including cognitive impairment, peripheral neuropathy, and other neurological complications.[46-47] In leukemia patients with advanced HIV/AIDS, the synergistic effects of obesity and HIV-associated neuroinflammation further potentiate treatment-related neurotoxicity. HIV/AIDS is characterized by chronic immune activation and neuroinflammation, which may exacerbate the neurotoxic effects of chemotherapy agents and increase susceptibility to cognitive impairment and other neurological complications. Therefore, the presence of obesity and advanced HIV/AIDS in leukemia patients necessitates careful consideration of their combined effects on treatment-related neurotoxicity, with targeted interventions aimed at mitigating these risks and improving outcomes.[48-50]

Clinical Implications and Interventions

The impact of obesity on treatment-related neurotoxicity in leukemia patients with advanced HIV/AIDS has significant clinical implications for patient care and management. Healthcare providers must recognize the heightened risk of neurotoxicity in obese individuals undergoing chemotherapy and implement targeted interventions to mitigate these risks and improve treatment outcomes. Comprehensive assessment of obesity-related risk factors, such as Body Mass Index (BMI), metabolic parameters, and adipokine levels, is essential for identifying leukemia patients with advanced HIV/AIDS who are at higher risk of treatment-related neurotoxicity. Routine monitoring of metabolic parameters, including glucose and lipid levels, can help identify metabolic disturbances that may exacerbate neurotoxicity and guide interventions aimed at optimizing metabolic health.[51-53]

Targeted interventions aimed at mitigating obesity-related inflammation and oxidative stress may help reduce the incidence and severity of treatment-related neurotoxicity in leukemia patients with advanced HIV/AIDS. Lifestyle modifications, including dietary counseling and physical activity programs, can help promote weight loss and improve metabolic health, thereby reducing the burden of obesity-related neurotoxicity. Additionally, pharmacological interventions targeting obesity-related inflammation and oxidative stress pathways may provide adjunctive benefits in mitigating treatment-related neurotoxicity. Furthermore, personalized treatment approaches that consider individual patient characteristics, including obesity status, HIV/AIDS disease stage, and leukemia subtype, are essential for optimizing treatment outcomes and minimizing neurotoxicity-related complications. Dose adjustments, treatment modifications, and supportive care measures tailored to the specific needs of obese individuals with advanced HIV/AIDS can help minimize treatment-related neurotoxicity while maximizing therapeutic efficacy. Multidisciplinary collaboration between healthcare providers, including oncologists, infectious disease specialists, neurologists, and nutritionists, is essential for developing comprehensive care plans that address the complex interplay between obesity, HIV/AIDS, and treatment-related neurotoxicity. Integrated approaches that incorporate neuroprotective strategies with leukemia treatment can optimize care and enhance quality of life for leukemia patients with advanced HIV/AIDS experiencing treatment-related neurotoxicity.[54-60]

Conclusion

The complex interplay between obesity, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), and treatment-related neurotoxicity presents significant challenges in the management of leukemia patients with advanced HIV/AIDS. Obesity exacerbates treatment-related neurotoxicity through alterations in systemic metabolism, inflammation, oxidative stress, and blood-brain barrier integrity. In the context of HIV/AIDS, the synergistic effects of obesity and HIV-associated neuroinflammation further potentiate treatment-related neurotoxicity, increasing susceptibility to cognitive impairment and other neurological complications. Recognizing the clinical implications of obesity on treatment-related neurotoxicity is essential for optimizing patient care and treatment outcomes. Comprehensive assessment of obesity-related risk factors, personalized treatment approaches, and multidisciplinary collaboration are crucial for developing comprehensive care plans that address the complex interplay between obesity, HIV/AIDS, and treatment-related neurotoxicity. Targeted interventions aimed at mitigating obesity-related inflammation and oxidative stress, such as lifestyle modifications and pharmacological interventions, may help reduce the incidence and severity of treatment-related neurotoxicity in leukemia patients with advanced HIV/AIDS. Through comprehensive assessment, personalized treatment approaches, and multidisciplinary collaboration, healthcare providers can optimize care and enhance quality of life for leukemia patients with advanced HIV/AIDS experiencing treatment-related neurotoxicity.

References

1. Akmaljon o‘g AM, Abdullajon o‘g‘li MS, Alimardonovich MH. LEUKEMIA–TYPES, CLINICAL APPEARANCES, DIAGNOSIS AND TREATMENT. Web of Medicine: Journal of Medicine, Practice and Nursing. 2024;2(4):10-17.
2. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. Int. J. Curr. Res. Biol. Med. 2023; 1:17-22.
3. Obeagu EI, Gnanavel K. An Insight on Acute Myeloid Leukemia: Pediatric Perspective. Journal home page: http://www. journalijiar. com. 2022;10(03).
4. Obeagu EI, Nakyeyune S, Muhimbura E, Owunna TA, Uwakwe OS. Evaluation of haematological manifestations in patients with acute myeloid leukaemia in a tertiary hospital in Uganda. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):58-63.
5. Yang JJ, Park TS, Wan TS. Recurrent cytogenetic abnormalities in acute myeloid leukemia. Cancer Cytogenetics: Methods and Protocols. 2017:223-245.
6. Gong JY, Zhang ZH, Zhang W, Wang HJ, Feng XF, Zhou J, Zhu GQ. Coexistence of recurrent chromosomal abnormalities and the Philadelphia chromosome in acute and chronic myeloid leukemias: report of five cases and review of literature. Molecular Cytogenetics. 2020; 13:1-9.
7. Obeagu EI, Obeagu GU. The Impact of Body Mass Index (BMI) on Immune Function in Leukemia Patients Living with HIV: A Review. Elite Journal of Immunology. 2024;2(4):73-92.

Citation: Obeagu EI. Obesity and Treatment-Related Neurotoxicity in Leukemia Patients with Advanced HIV/AIDS: A Review. Elite Journal of Medical Sciences, 2024; 2(5):31-39

8. Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV. AIDS: A Review. Elite Journal of Health Science. 2024;2(4):59-72.
9. Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. Elite Journal of Haematology, 2024; 2 (5).:39-54.
10. Naran K, Nundalall T, Chetty S, Barth S. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. Frontiers in microbiology. 2018; 9:405758.
11. Obeagu EI, Elamin EA, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. Elite Journal of Haematology, 2024; 2 (4).:23-35.
12. Obeagu EI, Obeagu GU. The Impact of Obesity on Overall Survival in Leukemia Patients Living with HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(4):26-45.
13. Obeagu EI, Obeagu GU. The Nexus Between Obesity and Leukemia Progression in HIV-Positive Individuals: A Review. Elite Journal of Haematology. 2024;2(4):180-98.
14. Vorri SC, Christodoulou I, Karanika S, Karantanos T. Human immunodeficiency virus and clonal hematopoiesis. Cells. 2023;12(5):686.
15. Pasco JA, Holloway KL, Dobbins AG, Kotowicz MA, Williams LJ, Brennan SL. Body mass index and measures of body fat for defining obesity and underweight: a cross-sectional, population-based study. BMC obesity. 2014; 1:1-7.
16. Aronne LJ. Classification of obesity and assessment of obesity-related health risks. Obesity research. 2002;10(S12):105S-115S.
17. Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association of body mass index and survival in pediatric leukemia: a meta-analysis. The American journal of clinical nutrition. 2016;103(3):808-817.
18. Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. The oncologist. 2010;15(10):1083-1101.
19. O'Sullivan J, Lysaght J, Donohoe CL, Reynolds JV. Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments. Nature reviews Gastroenterology & hepatology. 2018;15(11):699-714.
20. Mubtasim N, Moustaid-Moussa N, Gollahon L. The complex biology of the obesity-induced, metastasis-promoting tumor microenvironment in breast cancer. International journal of molecular sciences. 2022;23(5):2480.
21. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. EC Emergency Medicine and Critical Care. 2020;4(6):154-67.
22. Obeagu EI, Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. Int. J. Curr. Res. Med. Sci. 2021;7(7):29-41.
23. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Dysfunction in HIV-Related Hematological Malignancies: A Review. Elite Journal of Haematology, 2024; 2 (4).:105-22.
24. Obeagu EI, Obeagu GU. GATA-1 and HIV-Associated Myelodysplastic Syndromes: Pathogenesis and Treatment Strategies. Elite Journal of Medicine. 2024;2(4):1-8.
25. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets And Some Inflammation Markers Of Patients With

Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Oct 1;2(3):78-84.
26. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. Elite Journal of Health Science. 2023;1(1):12-22.
27. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. Elite Journal of Public Health. 2023;1(1):12-22.
28. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. Elite Journal of Public Health. 2023;1(1):1-11.
29. Yang JJ, Park TS, Wan TS. Recurrent cytogenetic abnormalities in acute myeloid leukemia. Cancer Cytogenetics: Methods and Protocols. 2017:223-245.
30. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Fortifying Efforts to Stop HIV in Newborns. Elite Journal of HIV. 2024;2(3):27-41.
31. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61
32. Obeagu EI OG. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health. 2023;1(1):23-33.
33. Obeagu EI, Obeagu GU. Strengthening Laboratory Systems for Ensuring Accurate Diagnoses in Mother-to-Child Transmission (MTCT) Prevention Programs in Uganda: A Narrative Review. Annals of Medicine and Surgery:10-97.
34. Das K, Tan P. Molecular cytogenetics: recent developments and applications in cancer. Clinical genetics. 2013;84(4):315-325.
35. Zahid MF, Malik UA, Sohail M, Hassan IN, Ali S, Shaukat MH. Cytogenetic abnormalities in myelodysplastic syndromes: an overview. International journal of hematology-oncology and stem cell research. 2017;11(3):231.
36. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
37. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
38. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
39. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
40. Forghieri F, Nasillo V, Bettelli F, Pioli V, Giusti D, Gilioli A, Mussini C, Tagliafico E, Trenti T, Cossarizza A, Maffei R. Acute myeloid leukemia in patients living with HIV infection: several questions, fewer answers. International Journal of Molecular Sciences. 2020;21(3):1081.
41. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, Pedersen C, Mogensen CB, Nielsen L, Obel N. Incidence, clinical presentation, and outcome of

progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. The Journal of infectious diseases. 2009;199(1):77-83.

42. Adebamowo CA, Casper C, Bhatia K, Mbulaiteye SM, Sasco AJ, Phipps W, Vermund SH, Krown SE. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low-and middle-income countries in Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2014;67:S17-26.
43. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
44. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
45. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
46. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
47. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
48. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
49. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
50. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

51. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
52. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. Journal of the American College of Cardiology. 2013;62(10):921-925.
53. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood cancer journal. 2016;6(2):e393-.
54. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
55. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
56. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
57. Daugherty PJ. Review of logistics and supply chain relationship literature and suggested research agenda. International Journal of Physical Distribution & Logistics Management. 2011;41(1):16-31.
58. Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL. Metabolic syndrome in patients with hematological diseases. Expert Review of Hematology. 2012;5(4):439-458.
59. Shanmuganathan N, Hiwase DK, Ross DM. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leukemia & lymphoma. 2017;58(12):2799-2810.
60. Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Current Hiv/aids reports. 2017; 14:93-100.